Skip to content

The study of key technologies for severe acute pancreatitis treatment

The study of key technologies for severe acute pancreatitis treatment

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036037
Enrollment
Unknown
Registered
2020-08-21
Start date
2020-12-01
Completion date
Unknown
Last updated
2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe acute pancreatitis

Interventions

hemofiltration:short-term hemofiltration
Control group:Conventional treatment

Sponsors

The First Affiliated Hospital of Naval Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18-75 years old; 2. Onset time <48h; 3. Acute persistent abdominal pain, with or without radiating pain; blood amylase is more than 3 times higher than the normal threshold; 4. Imaging findings such as abdominal ultrasound, enhanced CT or MRI showed signs of acute pancreatitis, accompanied by organ failure. According to the Atlanta classification criteria, the diagnosis was MSAP/SAP; 5. Agree to participate in this clinical study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Mild acute pancreatitis; 2. Pancreatitis of pregnancy; 3. MSAP/SAP has undergone surgical debridement and drainage, NOTES, ERCP and other interventional or surgical treatments; 4. Acute renal failure (diagnostic criteria: serum creatinine rise >=26.5umol/L (0.3mg/dL) within 48 hours; or serum creatinine rise to >=1.5 times the baseline value within 7 days; or urine output for 6 hours <0.5ml /Kg/h); 5. Complicated with diseases such as active bleeding, malignant tumor, hepatitis, chronic liver failure or chronic renal failure; 6. Pregnant women, patients with mental illness; 7. The researcher believes that there are any other factors that are not suitable for selection or that affect the participants' participation in the research.

Design outcomes

Primary

MeasureTime frame
SIRS duration;

Secondary

MeasureTime frame
Effective treatment rate;Mortality;Total hospital days;Hospital charge;

Countries

China

Contacts

Public ContactDu Yiqi

Changhai Hospital

duyiqi@hotmail.com+86 13801993592

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026